Aurobindo Pharma Full Year 2025 Earnings: EPS Misses Expectations

Simply Wall St · 05/28 00:30

Aurobindo Pharma (NSE:AUROPHARMA) Full Year 2025 Results

Key Financial Results

  • Revenue: ₹317.2b (up 9.4% from FY 2024).
  • Net income: ₹34.9b (up 9.9% from FY 2024).
  • Profit margin: 11% (in line with FY 2024).
  • EPS: ₹59.81 (up from ₹54.15 in FY 2024).
earnings-and-revenue-growth
NSEI:AUROPHARMA Earnings and Revenue Growth May 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Portfolio Valuation calculation on simply wall st

Aurobindo Pharma EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.6%.

Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Aurobindo Pharma's balance sheet and an in-depth analysis of the company's financial position.